PepLib Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
200
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$44M
- Investors
-
21
PepLib General Information
Description
Developer of peptide-leading drugs intended to serve the medical sector in China. The company is platform-based, specialized in the discovery of peptide-leading drugs, focusing on development, production, sale of large-capacity peptide libraries and development of technical services for the screening of new peptides.
Contact Information
Website
www.peplib.cnCorporate Office
- Building 5, Modern Service Industry Headquarters Park
- Number 1769 Yunlong Avenue, Yunlong Demonstration Zone
- Zhuzhou, Hunan 412011
- China
Corporate Office
- Building 5, Modern Service Industry Headquarters Park
- Number 1769 Yunlong Avenue, Yunlong Demonstration Zone
- Zhuzhou, Hunan 412011
- China
PepLib Timeline
PepLib Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series C) | 12-May-2026 | $44M | Completed | Generating Revenue | ||
| 5. Later Stage VC (Series B) | 23-Jul-2025 | Completed | Generating Revenue | |||
| 4. Secondary Transaction - Private | 29-Jun-2022 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A1) | 29-Apr-2021 | Completed | Generating Revenue | |||
| 2. Secondary Transaction - Private | 16-Jun-2020 | $14.5M | Completed | Generating Revenue | ||
| 1. Early Stage VC (Series A) | 26-Jul-2019 | $14.5M | $14.5M | Completed | Generating Revenue |
PepLib Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
PepLib Patents
PepLib Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026223726-A1 | Polypeptide specifically binding to transferrin receptor 1 (tfr1) and use thereof | Pending | 23-Apr-2025 | ||
| WO-2026145793-A1 | Polypeptide specifically binding to gpc3, and drug conjugate thereof and use thereof | Pending | 06-Jan-2025 | ||
| WO-2026145795-A1 | Polypeptide targeting and binding to gpc3, and drug conjugate thereof and use thereof | Pending | 06-Jan-2025 | ||
| WO-2026145794-A1 | Polypeptide targeting gpc3, and drug conjugate thereof and use thereof | Pending | 06-Jan-2025 |
PepLib Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
PepLib Investors (21)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aier Healthcare Investment | Corporate Venture Capital | Minority | ||
| Gaorong Ventures | Venture Capital | Minority | ||
| Jifeng Ventures | Venture Capital | Minority | ||
| LAV (Lilly Asia Fund) | Corporate Venture Capital | Minority | ||
| Sherpa Capital | Corporation | Minority |
PepLib FAQs
-
When was PepLib founded?
PepLib was founded in 2017.
-
Where is PepLib headquartered?
PepLib is headquartered in Zhuzhou, China.
-
What is the size of PepLib?
PepLib has 200 total employees.
-
What industry is PepLib in?
PepLib’s primary industry is Biotechnology.
-
Is PepLib a private or public company?
PepLib is a Private company.
-
What is the current valuation of PepLib?
The current valuation of PepLib is .
-
What is PepLib’s current revenue?
The current revenue for PepLib is .
-
How much funding has PepLib raised over time?
PepLib has raised $106M.
-
Who are PepLib’s investors?
Aier Healthcare Investment, Gaorong Ventures, Jifeng Ventures, LAV (Lilly Asia Fund), and Sherpa Capital are 5 of 21 investors who have invested in PepLib.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
